ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2784

Mesenchymal Stem Cells Ameliorate Lupus By Promoting T Cell Apoptosis Via Bcl-2/Bim Independent Pathway in MRL/Lpr Mice

Saisai Huang1, Dandan Wang2 and Lingyun Sun1, 1Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, 2Department of Rheumatology and immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: apoptosis and mesenchymal stem cells, Lupus

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Systemic Lupus Erythematosus – Animal Models - Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus (SLE) is an inflammatory autoimmune disease, involving in dysfunction of many organs. The abnormality of apoptosis plays an important role in the pathogenesis of SLE. Umbilical cord (UC)-derived mesenchymal stem cells (MSCs) have been confirmed to exert therapeutic effects on SLE. However, whether the benefit effects of UC-MSCs on SLE were mediated by regulating apoptosis remains to be elucidated. Mesenchymal stem cells (MSCs) have recently been used successfully in humans to control a lot of diseases. However, the mechanisms involved in their immunomodulatory effects remain a matter of debate. Here we explored whether lymphocytes apoptosis involved in the therapeutic effects of UC-MSCs in lupus mice.

Methods: One million human umbilical cord derived MSCs (UC-MSCs) were injected into B6.lpr mice via tail vein and 6 hours, 24 hours and four weeks later, all the mice were sacrificed, the apoptosis of lymphocyte in peripheral blood and spleen tissues as well as the expressions of Bim and Bcl-xl were detected by FACS, the immune cell subpopulations and cytokines in serum were also examined at 6 hours and 24 hours, respectively. The curative effects were assessed 4 weeks later.

Results:  UC-MSCs ameliorated disease progression of lupus mice, by regulating the percentage of immune cells, decreasing spleen weight and repairing kidney lesion. UC-MSCs promoted the lymphocyte apoptosis in peripheral blood and spleen tissues at 6 hours and 24 hours, reduced serum TGF-β1 levels, but did not affect Bim and Bcl-xl expressions in CD4+ and CD8+ T cells. Meanwhile, the percentage of Treg was significantly increased in MSCs transplantation group at both 6 and 24 hours. Reductions in the proportions of plasma cells, Th1,Th2 cells were also evident at 24 hours after MSCs infusion, while the levels of Tfh and Th17 cells had no significant change among different groups neither at 6 hours nor 24 hours.

Conclusion: MSCs may promote the apoptosis of T cells in lupus mice through regulating the immune cell subpopulation, decreasing total TGF-β1 in serum. Bim and Bcl-xl are not involved in it.


Disclosure: S. Huang, None; D. Wang, None; L. Sun, None.

To cite this abstract in AMA style:

Huang S, Wang D, Sun L. Mesenchymal Stem Cells Ameliorate Lupus By Promoting T Cell Apoptosis Via Bcl-2/Bim Independent Pathway in MRL/Lpr Mice [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/mesenchymal-stem-cells-ameliorate-lupus-by-promoting-t-cell-apoptosis-via-bcl-2bim-independent-pathway-in-mrllpr-mice/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mesenchymal-stem-cells-ameliorate-lupus-by-promoting-t-cell-apoptosis-via-bcl-2bim-independent-pathway-in-mrllpr-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology